文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

结直肠癌肝转移围术期化疗趋势:SEER-Medicare分析

Trends in perioperative systemic chemotherapy for resected colorectal liver metastases: A Surveillance, Epidemiology, and End Results-Medicare analysis.
PubMed 文献 · Surgery · 2026-05-11

该研究基于SEER-Medicare数据库(2000-2020)分析结直肠癌肝转移切除术患者围术期化疗的使用趋势及相关因素。在3752例切除患者中,54%接受了围术期化疗,使用率随时间略有下降,且与直肠原发和同时性转移相关;围术期化疗独立关联于改善的总生存,术前加术后方案获益最大。

要点

  • 肝转移切除患者中54%接受围术期化疗,使用率逐年略降。
  • 直肠原发和同时性转移者更可能接受围术期化疗。
  • 围术期化疗独立改善总生存,术前加术后方案HR 0.54。

核心结论

  • 围术期化疗用于半数肝转移切除患者,随时间变化小,并与改善的总生存相关,支持继续多模式管理。

研究设计与样本

  • 基于SEER-Medicare(2000-2020)的回顾性队列研究,纳入肝脏仅有的结直肠癌肝转移行肝切除术患者。

主要发现

  • 42235例肝转移患者中3752例(9%)行切除术,其中54%接受围术期化疗(14%仅术前,22%仅术后,18%术前加术后)。

临床怎么用

  • 肝转移切除前可考虑围术期化疗,尤其直肠原发或同时性转移患者。
  • 术前加术后化疗方案可能与最大生存获益相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment strategy for patients undergoing curative-intent resection of colorectal liver metastases remains uncertain. While perioperative and adjuvant chemotherapy are widely used, randomized trials have not demonstrated a consistent overall survival benefit, and guidelines continue to endorse approaches ranging from surgery alone to multimodal therapy. Randomized studies evaluating perioperative or adjuvant chemotherapy-along with trials incorporating biologic therapy-have shown improvements in disease control but inconsistent overall survival benefit. We evaluated national trends in perioperative chemotherapy use and factors associated with receipt over 2 decades. METHODS: Using Surveillance, Epidemiology, and End Results-Medicare (2000-2020), we identified patients who underwent hepatectomy for liver-only colorectal liver metastases. Perioperative chemotherapy was defined as systemic therapy within 6 months before surgery, 4 months after, or both. Temporal trends were assessed, multivariable logistic regression identified predictors of treatment, and overall survival was evaluated with Kaplan-Meier and adjusted Cox models. RESULTS: Among 42,235 patients with liver-only metastases, 3,752 (9%) underwent resection; 54% of these received perioperative chemotherapy (14% preoperative only, 22% postoperative only, and 18% both). Use declined modestly over time (odds ratio per year, 0.97; 95% confidence interval, 0.95-0.98; P < .001). Chemotherapy was more common with rectal primaries (odds ratio, 1.42; 95% confidence interval, 1.05-1.92; P = .02) and synchronous disease (odds ratio, 1.57; 95% confidence interval, 1.30-1.92; P < .001) but less likely in patients ≥75, <65, and with overlapping or unspecified primaries. Perioperative chemotherapy was independently associated with improved overall survival, greatest with both preoperative and postoperative regimens (hazard ratio, 0.54; 95% confidence interval, 0.47-0.60; P < .001). CONCLUSION: In this national cohort of adults, perioperative chemotherapy was used in half of patients undergoing hepatectomy for colorectal liver metastases with minimal change over time and was associated with improved survival, supporting continued multimodal management.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Vieira C, Silva M, Verma C, et al. Trends in perioperative systemic chemotherapy for resected colorectal liver metastases: A Surveillance, Epidemiology, and End Results-Medicare analysis. Surgery. 2026. PMID: 42114466. doi:10.1016/j.surg.2026.110234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。